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The extent of lymph node metastasis is a prognostic
indicator of disease progression in many malignan-
cies. Current noninvasive imaging technologies for
the clinical assessment of lymph node metastases
are based on the detection of cancer cells and com-
monly suffer from a lack of sensitivity. Recent evi-
dence has indicated that the expansion of lymphatic
networks (ie, lymphangiogenesis) within tumor-
draining lymph nodes might be the earliest sign of
metastasis. Therefore, we recently developed a non-
invasive imaging method to visualize lymph node
lymphangiogenesis in mice using radiolabeled anti-
bodies against the lymphatic vessel endothelial hya-
luronan receptor-1 (LYVE-1) as well as positron emis-
sion tomography (PET). This technique, termed
anti-LYVE-1 immuno-PET, was found to be very sensi-
tive in the detection of metastasis to the lymph nodes.
However, lymphatic vessel expansion to the lymph
nodes can also be induced by inflammation, and it is
currently unclear whether such vessel expansion is
reversed once inflammation has resolved. Detection
of residual inflammation-induced lymph node lymp-
hangiogenesis, thus, might hamper the identification
of metastasized lymph nodes. In this study, we there-
fore used a well-established mouse model of inflam-
mation in the skin to investigate whether lymphatic
vessels in the lymph nodes regress on resolution of
inflammation. Our data reveal that the lymphatic net-
work indeed regresses on the resolution of inflamma-
tion and that we can image this process by anti-LYVE-1
immuno-PET. (Am J Pathol 2012, 180:874–879; DOI:
10.1016/j.ajpath.2011.11.010)
Metastasis to the lymph nodes is a prognostic indicator
for disease progression in many malignancies. Current
noninvasive imaging technologies to assess lymph node
metastases in clinics are based on the detection of can-
874cer cells. However, these methods have limited sensitiv-
ities because a large number of tumor cells are required
for reliable detection.1 Recently, our group, along with
others, found that cancers can induce the expansion of
the lymphatic vasculature (lymphangiogenesis) in drain-
ing lymph nodes in experimental models and in cancer
patients.2–7 Importantly, lymph node lymphangiogenesis
occurs very early during the process of tumor metastasis,
and it is associated with the spread of cancer cells to
lymph nodes and organs.4,7 Because lymphatic vessel
expansion is already induced at the beginning of the
metastatic process, we have previously suggested that it
might serve as an early indicator for cancer metastasis to
the lymph nodes.8 We have, therefore, recently devel-
oped a method termed anti-lymphatic vessel endothelial
hyaluronan receptor-1 (LYVE-1) immuno-positron emis-
sion tomography (PET) to image lymph node lymphan-
giogenesis noninvasively in vivo.8 This technique is based
on the intravenous injection of a radioactively-labeled
antibody against LYVE-1, which is almost exclusively ex-
pressed on the lymphatic vessels.9,10 Subsequently, the
increased accumulation of injected 124I-anti-LYVE-1 anti-
body in the lymphangiogenic lymph nodes is imaged by
PET. Anti-LYVE-1 immuno-PET detected lymphatic vessel
expansion in metastasized lymph nodes that were not
detected by 18F-fluorodeoxyglucose-PET that is currently
applied in clinics.8 These data suggested that imaging of
lymph node lymphangiogenesis might be a new strategy
for the early detection of cancer metastasis.
Studies in experimental models, however, showed that
lymphatic network expansion in the lymph nodes can
also be induced by inflammation, and we have demon-
strated that this process is detected by anti-LYVE-1 im-
muno-PET as well.8,11–13 Currently, it is unclear whether
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tion. In a model of bacterial-induced airway inflammation,
lymphatic vessels in the trachea persisted after the in-
flammation had subsided.14 It is thus conceivable that
detection of persistent lymph node lymphangiogenesis,
after previously regressed inflammatory processes in the
draining area of the sentinel lymph node, in cancer pa-
tients might hamper the reliable identification of meta-
static lymph nodes. In this study, therefore, we aimed to
investigate whether lymphatic vessel expansion in the
lymph nodes is reversible, using an established model of
inflammation in the skin.12 After induction of a delayed-
type hypersensitivity reaction in the ear skin, these mice
develop skin inflammation that is associated with pro-
nounced expansion of the lymphatic network within the
draining superficial parotid lymph nodes (also termed
auricular lymph nodes). After discontinuing the inflamma-
tory stimulus, the inflammation in the ear skin resolves.
Our results reveal that the expansion of the lymphatic
network in the lymph nodes is indeed reversed after
resolution of inflammation and that this process can be
imaged by anti-LYVE-1 immuno-PET.
Materials and Methods
Inflammation-Induced Lymph Node
Lymphangiogenesis
Female FVB mice (Charles River Laboratories, Wilmington,
MA) were assigned into three treatment groups (n  3 per
group): i) mice in which delayed-type hypersensitivity (DTH)
reactions were induced in the ear skin (inflammation group);
ii) mice in which DTH responses were induced as in the
inflamed group, and in which the inflammation was subse-
quently allowed to regress (regression group); and iii) un-
treated control mice (control group) (Figure 1A).
DTH reactions were induced in the ear skins as de-
scribed.12 Briefly, the mice were sensitized by topical
application of 2% of the allergen oxazolone (4-ethoxym-
ethylene-2 phenyl-2-oxazoline-5-one; Sigma, St. Louis,
MO) in acetone:olive oil (4:1 by volume) to their shaved
abdomen (50 L) and to the skin of each paw (5 L
each). Five days after sensitization (study day zero) and
from then on every other day until study day 9, 10 L of
a 1% oxazolone solution was applied topically to each
side of the ears to induce inflammation in the ear skin and
lymphatic vessel expansion in the ear draining lymph
nodes.12 Mice of the inflamed groupwere then injectedwith
124I-anti-LYVE-1 antibody and imaged by PET as described
as follows. In contrast, in the regression group, oxazolone
treatment was stopped after study day 9, and themice were
kept for an additional 3 months, to allow the inflammation in
the ear skin to regress, and were then subjected to anti-
LYVE-1 immuno-PET. Ear thickness was measured before
the oxazolone challenge and was repeatedly measured
after the challenge using calipers, which were used to read-
out inflammation. At the time of PET imaging, all mice were
in between 22- and 24-weeks-old.
Before the PET experiments, normal uptake of radiola-
beled iodine by the thyroid glands and by iodine sym-porters in the intestine was blocked by administration of
potassium iodide in the drinking water starting 4 days
before injection of the radioactively labeled antibody, and
by oral administration of sodium perchlorate 1 hour be-
fore antibody injection. All animal experiments were ap-
proved by the cantonal veterinarian office Zurich (Kan-
tonales Veterinäramt Zürich).
Radioiodination and PET Imaging
Radioiodination of anti-LYVE-1 antibody was performed
as described.8 Briefly, three batches of 180 g anti-
LYVE-1 antibody (clone 223322, R&D Systems, Minneap-
olis, MN) were each labeled with 74 MBq Na124I (IBA
Molecular, Louvain-La-Neuve, Belgium) by the chloram-
ide T method. Then, the 124I-anti-LYVE-1 antibody was
purified with PD-10 columns (GE Healthcare, Chalfont St.
Giles, UK). Subsequently, 38 g of 124I-anti-LYVE-1 anti-
body (11.1–12.4 MBq) were injected intravenously into
the tail veins of the mice of the three treatment groups.
Within 14 to 25 hours after antibody injection, the mice
were scanned using a GE Vista/CT camera (GE Health-
care) as described.15 For in vivo PET scanning, mice
were anesthetized with isofluorane (Abbott Laboratories,
Abbott Park, IL) in an air/oxygen mixture and monitored
during PET scanning, as described.16 Whole-body PET
data were acquired in two bed positions (30 minutes
acquisition time per position) and were reconstructed in a
single time frame, with pixel sizes of 0.3875 mm and
0.775 mm in the transverse and axial directions, respec-
tively. After scanning, the mice were sacrificed and the
radioactivity in the superficial parotid lymph nodes was
measured using a gamma counter (1480 Wizard Auto-
matic Gamma Counter, Perkin Elmer, Waltham, MA).
Data were corrected for the body weight of the mice and
variations of the injected dose. PET sections were dis-
played with a fixed gray scale for comparison between
different mice.
Microradiography and Immunofluorescence
Analysis
After the PET experiments, the animals were sacrificed and
the superficial parotid lymph nodes were frozen in optimal
cutting temperature (OCT) compound (Sakura Finetec,
Zoeterwoude, Netherlands). The lymph nodes were cut in
7 m sections and fixed with 4% paraformaldehyde in PBS.
Air-dried sections were coated with Kodak autoradiography
emulsion type NTB (Carestream Health, Inc., Rochester,
NY), and developed according to the manufacturer’s in-
structions after 2 weeks exposure time. Alternatively, sec-
tions were fixed with 4% paraformaldehyde in PBS, incu-
bated with an Alexa Fluor (AF) 594 conjugated donkey
anti-rat IgG antibody (Invitrogen, Carlsbad, CA), and co-
stained with a rabbit anti-mouse LYVE-1 antibody (Angio-
bio, Del Mar, CA) detected by an AF488 donkey anti-rabbit
IgG antibody (Invitrogen). Sections were analyzed with an
AxioScop2MOT plusmicroscope (Zeiss, Oberkochen, Ger-
many) and images were captured with an AxioCam MRc
camera (Zeiss) using the Axio-Vision 4.7 software.
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Total cellular RNA was isolated from frozen superficial pa-
rotid lymph nodes using a TissueLyser, stainless steel
beads, and the RNeasy Plus Micro kit (all from QIAGEN,
Hilden, Germany). RNA (1.2 g) was used to synthesize
cDNA using the High-Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems, Foster City, CA). The expres-
sion of murine interferon (IFN)-, hepatocyte growth factor,
Prox1, vascular endothelial growth factor (VEGF)-A, -C, and
-D was investigated by TaqMan real-time PCR using the AB
7900 HT Fast Real-Time PCR System (Applied Biosystems)
and quantified using the 2CT method.17 The probes and
primers for IFN- (Mm01168134_m1), hepatocyte growth
factor (Mm01135193_m1), Prox1 (Mm00435971_m1),
VEGF-A (Mm00443258_m1), VEGF-C (Mm01202432_m1),
and VEGF-D (Mm00438965_m1) were predesigned. Eachreaction was multiplexed with -actin (4352341E; all from
Applied Biosystems) as a reference gene and all data were
normalized based on the expression levels of -actin (n 3
per group).
Results
Induction and Resolution of Skin Inflammation
To investigate whether resolution of inflammation leads to
the regression of the expanded lymphatic vasculature in the
lymph nodes, we used an established mouse model of ear
skin inflammation.12 After topical application of the contact
sensitizer oxazolone, the mice developed inflammation in
the ear skin that was associated with inflammation and
re 1. Inflammation-induced reversible increase of ear thickness. A: The ears
ild-type FVB mice were repeatedly treated with oxazolone to induce inflam-
on in the skin, which resulted in increased ear thickness (inflammation
p). After the oxazolone treatment was discontinued, the ear thickness grad-
decreased (regression group) (n  3 mice per group). Arrow: Time point
ositron emission tomographic (PET) imaging of the inflammation group.
whead: Time point of PET imaging of the regression group. B, C: Repre-
ative pictures of ears of mice from the control (B), inflammation (C), and
ession group (D) at the day of PET imaging. The redness and swelling
ced by the delayed-type hypersensitivity (DTH) response (panel C) had
ided in the regression group (panel D). E: The lymph node weights in-
sed on inflammation and decreased again after inflammation resolution. F:
rferon (IFN)- mRNA levels were increased in the inflamed compared to the
rol and regressed lymph nodes. Data represent mean SD *; P 0.05. G–K:
A levels of the lymphangiogenic factors VEGF-A (G), VEGF-C (H), VEGF-D
and hepatocyte growth factor (HGF) (J), and of the lymphatic transcription
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before and after DTH-response induction as a readout of
inflammation. Oxazolone treatment induced reddening and
inflammation of the ear skin and increased the ear thickness
from 148  2 m before inflammation to 520  8 m at
study day nine (Figure 1, A–C). After discontinuation of the
oxazolone treatment, the ear erythema gradually disap-
peared, and after 3 months the ear thickness was reduced
to 198  10 m, which indicated that the inflammation had
largely resolved. In addition to inflammation in the ear skin,
the DTH response provoked a 5.6-fold increase in lymph
node weights that was almost reversed in the regressed
group (Figure 1E). Accordingly, the mRNA expression lev-
els of the inflammatory cytokine IFN- were significantly
increased in inflamed lymph nodes, and were back to nor-
mal levels in the regression group (Figure 1F). No major
changes in mRNA expression were observed for the lymp-
hangiogenic factors VEGF-A, VEGF-C, VEGF-D, and hepa-
tocyte growth factor, or for the lymphatic transcription factor
Prox1 (Figure 1, G–K).
In Vivo PET Imaging Reveals Lymphatic Vessel
Expansion and Regression in Draining Lymph
Nodes
Next, we visualized the ear-draining superficial parotid
Figure 2. In vivo positron emission tomographic (PET) imaging of the lymp
vessel endothelial hyaluronan receptor-1 (LYVE-1) antibody. A–C: Normalize
groups (C) (n  3 per group) with higher magnifications of the cervical regi
lymph nodes (arrows) was stronger in inflammation than in the control gr
124I-anti-LYVE-1 antibody in the lymph nodes.lymph nodes by anti-LYVE-1 immuno-PET and assessedwhether the radioactive signals at these sites decreased
after resolution of the inflammation. Thus, we radiola-
beled the anti-LYVE-1 antibody with the positron emitter
124I and administered it intravenously into mice of the
control, inflammation, and the regression group. In vivo
PET imaging was performed 14 to 25 hours after antibody
injection. Normalized serial sections of the mice revealed
much stronger radioactive signals in the superficial pa-
rotid lymph nodes of the inflammation group compared to
the control group (Figure 2, A and B), indicating that the
lymphatic vasculature had indeed expanded in lymph
nodes draining inflamed skin. To validate this finding, we
sacrificed the mice and measured the radioactivity in the
isolated superficial parotid lymph nodes with a gamma
counter. Inflamed lymph nodes had accumulated 7.3-fold
more 124I-anti-LYVE-1 antibody (6.5  105  0.6  105
cpm) than control lymph nodes (8.9  104  3.1  104
cpm) (Figure 3). The radioactive signals in the lymph nodes
of 124I-anti-LYVE-1 antibody injected mice were specific
since 124I-labeled control IgG does not accumulate in the
lymphatic vessels, as we have previously shown.8
Next, we investigated normalized sections of the mice
of the regression group, in which inflammation was al-
lowed to resolve. Importantly, the signal in these mice
was strongly reduced compared to the inflammation
group (Figure 2, B and C). The clear difference in anti-
ssel regression in superficial parotid lymph nodes using 124I-anti-lymphatic
PET sections of mice from the control (A), inflammation (B), and regression
w. The accumulation of 124I-anti-LYVE-1 antibody in the superficial parotid
gression of inflammation subsequently resulted in reduced accumulation ofhatic ve
d serial
ons belobody accumulation was confirmed by measuring the iso-
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antibody accumulation (2.1  105  0.7  105 cpm)
compared to the inflamed lymph nodes (Figure 3A).
Inflammation Resolution Leads to Lymphatic
Vessel Regression
In an additional step, we determined the location of the
injected 124I-anti-LYVE-1 antibody in the superficial pa-
rotid lymph nodes of the different groups after PET imag-
Figure 3. Reversible expansion of the lymphatic network in the lymph
nodes on inflammation. A: Radioactivity in the superficial parotid lymph
nodes of the mice was measured subsequent to positron emission tomo-
graphic (PET) imaging. Inflammation in the ear skin resulted in increased
antibody accumulation in the draining lymph nodes. On inflammation res-
olution, antibody accumulation was decreased again (n  3 mice per group;
cpm  counts of gamma quantum stemming from 124I decays per minute).
B–D: Immunofluorescence analysis of a representative tissue section from an
inflamed superficial parotid lymph node. The injected 124I-anti-LYVE-1 anti-
body (B) completely co-localized with LYVE-1 stained lymphatic vessels (C);
(merge, D). Scale bars: 100 m. E–G: Higher magnifications of panels B–D,
respectively. Scale bars: 50 m. H–J: Microradiographs of tissue sections of
control (H), inflammation (I), and regression groups (J) mice following
immuno-PET imaging reveal increased accumulation of the injected 124I-anti-
LYVE-1 antibody (black signal) in the inflamed compared to the regressed or
the control lymph node. Scale bars  100 m. K–M: Low magnifications of
micrographs of control, inflamed, and regressed lymph nodes, respectively.
Scale bars: 200 m.ing. We detected the injected 124I-anti-LYVE-1 antibodyby a fluorescently labeled anti-rat IgG antibody on lymph
node sections (Figure 3, B and E). Importantly, the local-
ization of the injected anti-LYVE-1 antibody overlapped
completely with the localization of LYVE-1 when detected
by external co-staining with a rabbit antibody to LYVE-1
(Figure 3, C, D, F, and G), which indicates that all lym-
phatic structures in the lymph nodes were reached by the
antibody.
Microradiography of superficial parotid lymph node
sections from the control, inflammation, and regression
groups revealed equally strong signals of the injected
124I-anti-LYVE-1 antibody on the lymphatic vessels (Fig-
ure 3, H-M), indicating that the lymphatic vessels of the
three groups were equally accessible for the antibody.
However, microradiographies revealed a much larger
amount of lymphatic vessels in the inflamed than in the
control lymph nodes (Figure 3, H, I, K, and L), which
confirms the increased radiolabeled antibody accumula-
tion observed in PET imaging and in the excised super-
ficial parotid lymph nodes. Importantly, the amount of
lymphatic vessels decreased on inflammation regression
(Figure 3, J and M).
Taken together, these data indicate that the lymphatic
vasculature in the lymph nodes (that has expanded on
inflammation) regresses after resolution of inflammation and
we can image this process by anti-LYVE-1 immuno-PET.
Discussion
In this study we have shown that inflammation-induced lym-
phatic vessel expansion in lymph nodes is reversible and
we can image this process by anti-LYVE-1 immuno-PET.
We have previously found that solid tumors induce the
expansion of the lymphatic vasculature in the draining
lymph nodes of experimental mouse models, along with
others,2–5,18 and in melanoma and breast cancer pa-
tients.6,7 This process starts at the beginning of cancer
metastasis and therefore its noninvasive visualization
might represent a novel approach for cancer metastasis
detection.8 The detection of inflammation-induced lymph
node lymphangiogenesis might complicate the identifi-
cation of metastasized lymph nodes. However, the data
presented here indicate that inflammation-induced lym-
phatic vessel expansion in the lymph nodes is reversible.
Thus, resolved inflammations will not be detected (or will
only weakly be detected) by noninvasive lymphatic ves-
sel imaging. Because inflammation and tumors rarely
co-exist at the same location and drain into the same
lymph nodes, detection of lymph node lymphangiogen-
esis might therefore likely indicate cancer metastasis to
these sites and not a previous occurrence of inflamma-
tion in the area that drains to the sentinel lymph node.
Currently, there are few data on the possible molecular
mechanisms that regulate lymphatic vessel regression. A
recent report indicated that IFN- might mediate reduction
of lymphatic vessels in a model of bacterial pathogen-in-
duced lymph node lymphangiogenesis.18 However, in our
study we found increased IFN- transcript levels in the
inflamed compared to the control and the regressed
lymph nodes, therefore largely ruling out a major role of
Imaging of Lymph Node Lymphangiogenesis 879
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ously, lymphangiogenesis in the lymph nodes has been
reported to be induced by vascular endothelial growth
factors secreted by macrophages and B-cells.11,13 Our
expression studies, however, showed no major changes
in the mRNA expression levels of the lymphangiogenic
factors hepatocyte growth factor and VEGF-A, -C, and -D
in the affected lymph nodes. We have previously found
that lymph node lymphangiogenesis in the inflammation
model used in this study was induced by VEGF-A that
drained from the inflamed ear skin.12 Thus, reduced skin
inflammation in the regressed group likely resulted in
diminished amounts of VEGF protein transported via lym-
phatic vessels to the draining lymph nodes. Interestingly,
lymphatic vessel regression only started once the inflam-
mation had substantially resolved. One month after dis-
continuing the inflammatory stimulus, we have not found
a decrease in 124I-anti-LYVE-1 antibody accumulation in
the lymph nodes compared to the inflamed mice (data
not shown).
In a model of bacterial-induced airway inflammation
lymphatic vessels in the trachea only partially regressed
after the inflammation had subsided. However, in this
model, lymphatic vessels were investigated in the periph-
eral tissue itself, whereas we analyzed the lymphatic ves-
sels in the lymph nodes, not in the peripheral (inflamed)
tissue. Thus, there may be model-specific and site-spe-
cific differences of the lymphatic vessel response to in-
flammation regression.
In conclusion, our data indicate that inflammation does
not leave a permanent lymphatic vessel “scar” in the
lymph nodes, and they also suggest that imaging of
lymphatic vessel expansion in lymph nodes might be a
promising strategy for the early detection of cancer me-
tastasis.
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